GERMANTOWN, Maryland and
HILDEN, Germany, December 15, 2017 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN, Frankfurt Stock Exchange: QIA) and
Oxford Immunotec Ltd. (NASDAQ: OXFD) announced today that they have
reached a settlement in the lawsuit in the U.S. District Court for
the District of Massachusetts in
Boston (15-cv-13124-NMG) alleging
patent infringement in relation to QIAGEN's QuantiFERON®-TB Gold
and QuantiFERON®-TB Gold Plus products.
Under terms of the agreement, all pending claims between Oxford
and QIAGEN and the co-defendants have been resolved. As part of the
settlement, Oxford has granted QIAGEN a royalty-free, non-exclusive
license that extends to all current and future customers of
QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus in exchange for a
one-time, lump-sum payment of $27.5
million. The settlement includes general releases of
all parties with no admissions of wrongdoing.
This agreement does not affect QIAGEN's adjusted EPS outlook for
the fourth quarter and full-year 2017 since these one-time costs
are excluded from adjusted results.
Click here for the full press release
https://corporate.qiagen.com/newsroom/press-releases/2017/20171215_QGEN_OXFD?sc_lang=en
Contacts:
QIAGEN
Investor Relations
John Gilardi
+49-2103-29-11711
e-mail:
ir@QIAGEN.com
Public Relations
Dr. Thomas Theuringer
+49-2103-29-11826
e-mail: pr@QIAGEN.com
SOURCE QIAGEN